These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 14974875)

  • 41. Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis.
    Athanasakis K; Ferrante SA; Kyriopoulos II; Petrakis I; Hill M; Retsa MP; Kyriopoulos J
    Clin Ther; 2015 Jul; 37(7):1529-40. PubMed ID: 26031617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
    Lin WA; Tarn YH; Tang SL
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1483-93. PubMed ID: 17081165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
    Nakamura J; Kobayashi K; Toyabe S; Aoyagi Y; Akazawa K
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):733-9. PubMed ID: 17700257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N
    Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Arguedas M
    Pharmacoeconomics; 2004; 22(7):477-8; author reply 478-9. PubMed ID: 15137884
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
    García-Contreras F; Nevárez-Sida A; Constantino-Casas P; Abud-Bastida F; Garduño-Espinosa J
    Arch Med Res; 2006 Jul; 37(5):663-73. PubMed ID: 16740439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
    Dan YY; Ferrante SA; Elbasha EH; Hsu TY
    Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
    Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
    J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
    Lo AO; Chan HL; Wong VW; Wong GL
    J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
    J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
    Foster GR
    Drugs; 2010; 70(2):147-65. PubMed ID: 20108989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Keating GM; Curran MP
    Drugs; 2003; 63(7):701-30. PubMed ID: 12656650
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden.
    Sennfält K; Reichard O; Hultkrantz R; Wong JB; Jonsson D
    Scand J Gastroenterol; 2001 Aug; 36(8):870-6. PubMed ID: 11495084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
    Manns MP; McHutchison JG; Gordon SC; Rustgi VK; Shiffman M; Reindollar R; Goodman ZD; Koury K; Ling M; Albrecht JK
    Lancet; 2001 Sep; 358(9286):958-65. PubMed ID: 11583749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.
    El Khayat HR; Fouad YM; El Amin H; Rizk A
    Trop Gastroenterol; 2012; 33(2):112-7. PubMed ID: 23025057
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R; Tabone M; Manca A; Pellicano R; Ciancio A; Rizzetto M
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.